Advancing Science. Improving Connections.

Zynerba is an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids.

Our People

Focusing on the unmet medical needs of patients with rare disorders and their families


Our Company

Progressing our mission to improve the lives of patients battling certain orphan diseases


Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions


Latest News


Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology

Read More

Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders

Read More

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome

Read More

Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

Read More

You are now leaving the Zynerba website

You are being redirectd to a third-party website. The terms and conditions of this third-party website may be different from and will govern your use of such website.

Continue (5) Cancel